Martin Nemansky, Ph.D, is Scientific Director at Pra International, Early Development Services, Bioanalytical Laboratory, The Netherlands.
Jerome Wilson and Martin Nemansky, explore some of the difficulties of implementing biomarkers during drug development.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial